Importantly, the emergence of multifunctional agents, combining MAO inhibition with antioxidant, anti-inflammatory, or cholinesterase-blocking activities, represents a particularly promising avenue to address the multifactorial nature of Parkinson’s pathology. This evidence concerns the gene BCHE and Parkinson disease.